Mizuho Maintains Neutral on Apellis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and keeps the price target at $60.
March 27, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mizuho maintains a Neutral rating on Apellis Pharmaceuticals with a $60 price target.
The maintenance of a Neutral rating and a $60 price target by Mizuho suggests that the analyst sees no immediate catalysts that would significantly change the stock's valuation in the short term. This could lead to a stable but uneventful performance for APLS shares in the near future.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90